Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00132769 | A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED) | PHASE2 | COMPLETED | 106 | — | — | Jan 1, 2005 | Nov 1, 2005 | Jul 30, 2015 | - | — |
Swollen joint count (SJC) was determined by assessing 66 joints (33 right side, 33 left side) for swelling using the following grading system: 0=Absent, 1=Detectable synovial thickening without loss of bony contours, 2=Loss of distinctiveness of bony contours, or 3=Bulging synovial proliferation with cystic characteristics. The total number of joints graded 1, 2, or 3 were then counted to yield the SJC. SJC ranged from 1-66, with increasing score indicating greater number of swollen joints. SJC was averaged over weeks 8, 10 and 12 to yield a Treatment Period Mean. Change from Baseline = Treatment Period Mean SJC - Baseline SJC.
| Arm | Type | Description |
|---|---|---|
| MK-0873 | EXPERIMENTAL | MK-0873 1.25 mg twice daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| MK-0873 | DRUG | MK-0873 1.25 mg twice daily for 12 weeks |
| Comparator: Placebo | DRUG | Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks |
Inclusion Criteria: * Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications * Other criteria also apply Exclusion Criteria: * Other major illnesses * Past history of certain other disorders * Certain prohibited medication...